bioecon Member area
Technology · Health & biomedicine / Therapeutics & platforms

In-vivo gene therapy: AAV and lentiviral vectors

One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.

Maturity 5/9 Risk: medium Advanced therapies US · CN · EU Science: why it works → verified 2026-07-23 · 8 Sources (0 independent)

1 · What it gives

In-vivo gene therapy delivers a functional therapeutic gene directly into a patient’s cells using a engineered viral vector, most often an adeno-associated virus (AAV) and, for ex-vivo-modified autologous products, a lentiviral vector. Since Luxturna became the first FDA-approved direct in-vivo gene therapy in December 2017, eight one-time AAV products have reached the US or EU market, including Zolgensma for spinal muscular atrophy at roughly 2.1 million US dollars per dose and Hemgenix for haemophilia B at about 3.5 million dollars — the world’s most expensive medicine at launch. More than 3000 children have received Zolgensma worldwide, and AAV manufacturing titers in suspension HEK293 cultures now routinely exceed 1e14 viral genomes per batch. Yet the field is also honest about its limits: BioMarin voluntarily withdrew Roctavian from the market in 2024 after poor commercial uptake despite durable five-year Phase 3 efficacy, a signal that clinical success and market viability are not the same.

The key directions of in-vivo gene therapy are:

  1. AAV serotype matching (AAV Serotype Matching): tissue-tropic capsids route the payload to the right organ — AAV2 for the retina (Luxturna), AAV9 across the blood-brain barrier (Zolgensma), AAV5 to hepatocytes (Hemgenix, Roctavian), AAVrh74 to skeletal and cardiac muscle (Elevidys).
  2. Liver-directed haemophilia platforms (Liver-Directed Haemophilia): a single infusion of an AAV5 or AAVrh74 vector encoding factor IX or VIII achieves multi-year clotting-factor expression, replacing lifelong prophylactic infusions (Hemgenix, Beqvez), though Roctavian’s withdrawal tempers the commercial narrative.
  3. Lentiviral ex-vivo platforms (Lentiviral Ex-Vivo): gammaretroviral and lentiviral vectors modify a patient’s own haematopoietic stem cells outside the body before re-infusion, the backbone of Bluebird’s Skysona and Zynteglo and Orchard’s Libmeldy for rare neurological and blood disorders.
  4. Manufacturing scale-up and capsid yield (Manufacturing Scale-Up): the move from adherent to suspension HEK293 transient transfection, with triple-plasmid systems and affinity chromatography, drives the titer and cost reductions needed to treat millions rather than thousands.

Sectoral value chain#

[capsid + payload design] ──> [plasmid & cell bank] ──> [transfection / production] ──> [harvest + lysis]
                                             │
                                  (AAV serotype selection)
                                             │
                                             ▼
[patient dosing] <─── [fill-finish + QC] <─────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Capsid & Payload Designserotype + transgene cassette selectionIn: sequence data, capsid library. Out: vector construct.
Plasmid & Cell BankGMP plasmid amplification and HEK293 bankIn: DNA, cells. Out: GMP plasmid, MCB.
Transfection / Productiontriple-plasmid transfection in suspension cultureIn: plasmids, cells, reagents. Out: crude viral lysate.
Harvest & Downstreamlysis, nuclease, affinity + ion-exchange chromatographyIn: lysate, resins. Out: purified capsids.
Fill-Finish & QCsterile fill, potency, identity, safety releaseIn: purified vector, vials. Out: drug product.
Clinical Deliveryone-time intravenous, subretinal or intrathecal dosingIn: drug product, clinical team. Out: treated patient.

Cross-cutting technologies of the sector:

  • Transient triple-plasmid transfection (Transient Transfection): rep/cap, helper and transgene plasmids co-transfected into HEK293 suspension cells for helper-virus-free AAV production.
  • Capsid engineering (Capsid Engineering): directed evolution and rational design of capsids that evade pre-existing neutralising antibodies and target novel tissues.
  • Tissue-specific regulatory cassettes (Tissue-Specific Cassettes): promoters such as LP1 or MHCK7 restrict transgene expression to hepatocytes or muscle, raising safety and expression.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    Capsid and cassette design
    A serotype is matched to the target tissue and a transgene cassette with a tissue-specific promoter is assembled in silico, then validated in rodent and large-animal models.
  2. 2
    Plasmid and cell bankStrains & cell lines
    GMP-grade rep/cap, helper and transgene plasmids are amplified in bacterial fermentation and a qualified HEK293 master cell bank is established and characterised for adventitious agents.
    Who can do this step matched automatically
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Platform and capabilities: end-to-end support from discovery to market approvals, with services spanning cell line creation, GMP/MO handling, CMC/PD/AD, MSAT …”
    Fermelanta Japan
    3,000 L pilot scale
    “is a Japan-based biomanufacturing/synthetic biology startup engineering fast-growing E.”
    CHITOSE Japan
    industrial scale
    “STABLE CELL LINE DEVELOPMENT SERVICE”
    ToolGen (KOSDAQ) South Korea
    “Toolgen is committed to conducting research for revamping genome editing technology and thus developing not only therapeutics for humans but plants and animals of which the genetic …”
    CRUST Group Singapore
    50,000L
    “2026-09-12 [AI and CRISPR combine to tackle crop breeding’s next challenge - AG Life Media — The article discusses a partnership between DNA Harvest Partners and ToolGen to …”
    Sanatech Seed Japan
    industrial scale
    “is a Japan-based agricultural biotech company (seed/crop development and sales, plus gene-edited functional food products) that focuses on CRISPR/Cas9-driven crop improvement, …”
  3. 3
    Transfection and harvest
    Triple-plasmid transfection of suspension HEK293 cells in stirred-tank bioreactors produces crude AAV, which is harvested by chemical lysis and nuclease digestion to release intracellular capsids.
  4. 4
    PurificationPurification & downstream
    Affinity chromatography captures AAV capsids, followed by anion-exchange polishing and diafiltration to remove empty capsids, host-cell protein and DNA, reaching purity above 95 percent full capsids in modern processes.
    Who can do this step matched automatically
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”
    HLB Genex (ex-GenoFocus) South Korea
    industrial scale
    “With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
    Space F South Korea
    “2026-07-12 [Korea's next drug lab is in orbit - The Korea Herald — Space LiinTech is advancing Korea’s foray into space-based drug research with autonomous microgravity platforms …”
    ScaleUp Bio Singapore
    10,000 L pilot scale
    “Core capabilities span pilot-industrial fermentation and downstream unit operations (centrifugation, TFF, chromatography, solvent extraction, spray/freeze drying) with cGMP …”
  5. 5
    Fill-finish and QCPackaging & fill-finishTesting & analytics
    The purified vector is formulated, sterile-filtered, filled into cryo-vials and released against potency, identity, residual host-cell and empty-capsid specifications under FDA OTP and EU ATMP GMP.
    Who can do this step matched automatically
    Esco Aster Singapore
    ✓ ISO 9001 5,000 L industrial scale
    “Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”
    Pakka (ex-Yash Pakka) India
    1940 MT per annum industrial scale
    “Pakka Limited (located in Ayodhya, India) provides regenerative packaging solutions for food products.”
    Turion Labs Singapore
    “Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”
    Ecoware India
    1,500 tons/
    “Our range of 135+ biodegradable and compostable products includes plates, bowls, cups, trays, takeaway containers and custom food packaging solutions trusted by restaurants, cafés, …”
    RWDC Industries Singapore
    industrial scale
    “2026-04-02 [A Major Step Forward in the Fight Against Microplastics — RWDC Industries is positioning itself as a leader in sustainable biopolymers, specifically Solon PHA, a fully …”
  6. 6
    Clinical dosingField application & services
    A one-time intravenous, subretinal or intrathecal infusion delivers the vector; patients are monitored for neutralising-antibody status and transgene expression, with multi-year durability now demonstrated for Luxturna, Zolgensma and Hemgenix.
    Who can do this step matched automatically
    Origin Agritech (NASDAQ: SEED) China
    industrial scale
    “Trait development: first-generation insect resistance and herbicide-tolerance (PEST/WEED) traits, with field trials and subsequent incorporation into elite inbred lines and partner …”
    DeHaat India
    “We also provide AI-enabled crop advisory to farmers for 30+ crops in regional languages.”

4 · Who delivers

Matched suppliers (matched automatically)

SartoriusGermanyProduceractive
MGI (BGI Group)ChinaProduceractive
MosquitoMateUnited StatesResearch / RTOactive
AgriLife (Som Phytopharma)IndiaResearch / RTOactive
PBS BiotechUnited StatesServices / consultingactive
icipeKenyaResearch / RTOactive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Spark Therapeutics🇺🇸 USALuxturna (AAV2-RPE65)first direct in-vivo GT, retinal subretinal deliveryCommercial
Novartis🇨🇭 SwitzerlandZolgensma (AAV9-SMN1)CNS crossing, >3000 patients treatedCommercial
Sarepta Therapeutics🇺🇸 USAElevidys (AAVrh74-micro-dystrophin)muscle-tropic capsid, DMD franchiseCommercial
Pfizer🇺🇸 USABeqvez (AAVrh74var-FIX)haemophilia B, one-time infusionCommercial
uniQure🇳🇱 NetherlandsHemgenix (AAV5-FIX-Padua)liver-directed, 5-year NEJM durabilityCommercial
YolTech Pharmaceuticals🇨🇳 ChinaAAV base-editor platformin-vivo editing, cardiovascular targetsPilot

5 · Rules & route to market

United States

The United States hosts the largest concentration of approved in-vivo gene therapy sponsors and the FDA’s Office of Therapeutic Products (OTP), which has cleared the majority of the world’s commercial AAV treatments.

capsid platforms, DMD leadership, haemophilia launches#

  • Spark Therapeutics (Luxturna): the 2017 RPE65 retinal therapy continues to lead inherited-retinal gene therapy with growing market penetration as the field’s first direct in-vivo product.
  • Sarepta Therapeutics (Elevidys): the AAVrh74 micro-dystrophin vector for Duchenne muscular dystrophy, accelerated in 2023 and expanded to ambulatory and non-ambulatory boys, is now the largest US in-vivo gene-therapy franchise by revenue, reported in the Q1 2026 results.
  • Pfizer (Beqvez): FDA- and Health Canada-approved fidanacogene elaparvovec for haemophilia B in 2024, adding a second one-time AAV haemophilia option alongside a candid commercial caution from the Roctavian withdrawal.
European Union

Europe authored the field’s regulatory backbone through the ATMP Regulation (EC) No 1394/2007 and hosts both the haemophilia-B originator and the CNS gene- therapy franchise.

SMA franchise, haemophilia origin, ATMP regulation#

  • Novartis (Zolgensma): the AAV9 onasemnogene abeparvovec for spinal muscular atrophy, with full-year 2025 and Q2 2026 sales reaffirming its place as the world’s most widely administered one-time in-vivo gene therapy, delivered across Swiss-based global manufacturing.
  • uniQure (Hemgenix): the Dutch originator of the AAV5 etranacogene dezaparvovec, whose five-year durability data published in the New England Journal of Medicine underpins the CSL-marketed haemophilia B therapy and the first patients treated commercially.
  • ATMP framework: EMA’s Committee for Advanced Therapies (CAT) provides the centralized authorisation route that licensed Zolgensma and Hemgenix across the bloc, predating several US approvals.
China

China’s in-vivo gene therapy is moving from CAR-T-adjacent lentiviral work into AAV-directed platforms, with NMPA pathways opening for domestic capsid engineering and base-editing programmes.

AAV base editing, lentiviral heritage, NMPA pathways#

  • YolTech Pharmaceuticals (尧唐生物): a Shanghai in-vivo gene-editing company founded in 2021, building AAV-delivered base-editor platforms for cardiovascular and metabolic targets, backed by a more than 300 million yuan B round led by the AstraZeneca-CICC healthcare fund.
  • Lentiviral heritage: China’s earlier approved gene therapies lean on ex-vivo lentiviral CAR-T platforms, providing the GMP and regulatory experience now flowing into AAV in-vivo candidates.
  • NMPA acceleration: the Centre for Drug Evaluation is opening priority review channels for AAV treatments for rare diseases, tracking the FDA OTP model.

6 · Money: tenders & grants

GrantFirst in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based …
National Institutes of Health · United States
Oct 15, 2027
364 days
GrantNIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
National Institutes of Health · United States
Jul 5, 2029
993 days
GrantBlueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the …
National Institutes of Health · United States
Aug 18, 2027
306 days
GrantDevelopment of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not …
National Institutes of Health · United States
Jan 25, 2028
466 days
GrantEnhancing ecodesign and circularity of construction products
European Commission · EU
Sep 22, 2027
341 days

7 · Tech stack & innovations

The in-vivo gene therapy stack rests on vector engineering, scalable production and immune management, each hardened by a decade of post-Luxturna learning.

  1. AAV capsid selection (AAV Capsid Selection):
    • serotype-tissue matching dictates efficacy: AAV2 for retina, AAV9 for CNS and systemic paediatric delivery, AAV5 and AAVrh74 for liver and muscle.
    • case: Zolgensma’s AAV9 crosses the blood-brain barrier to reach spinal motor neurons in SMA type 1.
  2. Suspension transient transfection (Suspension Transient Transfection):
    • triple-plasmid (rep/cap + helper + transgene) co-transfection in serum-free suspension HEK293 replaces adherent production for scale.
    • affinity chromatography (e.g. AVB Sepharose) plus anion-exchange polishing lifts batch titers above 1e14 viral genomes.
  3. Immune and expression engineering (Immune & Expression Engineering):
    • engineered and selected capsids evade pre-existing neutralising antibodies that would otherwise exclude up to 60 percent of adults from systemic AAV dosing.
    • tissue-specific promoters (LP1, MHCK7) confine transgene expression to hepatocytes or muscle, lifting both safety and expression durability.

Sources 8 · 0 independent · 8 producer sites

Producers' own sites 8

  1. Spark therapeutics producer checked 2026-07-21 · link not kept
  2. Novartis producer checked 2026-07-21 · link not kept
  3. Biomarin producer checked 2026-04-24 · link not kept
  4. Uniqure producer checked 2026-07-13 · link not kept
  5. Sarepta therapeutics producer checked 2026-07-13 · link not kept
  6. Bluebird bio producer checked 2026-07-09 · link not kept
  7. Pfizer producer checked 2026-06-14 · link not kept
  8. Yoltech producer checked 2026-07-23 · link not kept